Please provide your email address to receive an email when new articles are posted on . The study treatment, PT027, is a potential first-in class inhaled, fixed-dose combination rescue medication ...

Please provide your email address to receive an email when new articles are posted on . The American College of Allergy, Asthma & Immunology (ACAAI) and American Academy of Allergy, Asthma & ...

AstraZeneca already has its aging two-drug inhaler Symbicort as a maintenance treatment for asthma. Now, with a pair of trial wins, the company looks on track to have a novel doublet for controlling ...

Propeller Health’s connected inhaler technology helped to reduce usage of a rescue inhaler in a recent study of 495 asthma patients conducted at Dignity Health. “The research demonstrates that the ...

Credit: AstraZeneca. Airsupra combines albuterol, a short-acting beta2-agonist, and budesonide, an inhaled corticosteroid. Airsupra ® (albuterol/budesonide) is now available for the as-needed ...

AstraZeneca PLC (NASDAQ:AZN), a pharmaceutical and biotech firm based in Cambridge, UK, reported positive results from its Phase 3b Batura trial. The study found that Airsupra, its dual-action asthma ...

Young woman using asthma inhaler at home. The NDA submission is supported by data from the phase 3 MANDALA trial, which included 3132 patients with moderate to severe asthma. The Food and Drug ...

TEL AVIV, ISRAEL & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Respiratory, LLC., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the launch of AirDuo ® ...

The FDA approved a pressured, metered-dose inhaler containing albuterol and budesonide (Airsupra) for treating adults with asthma, drugmaker AstraZeneca announced. The combination, formerly known as ...

Acorda Therapeutics has launched a streaming commercial for Inbrija, a four-year-old rescue inhaler for Parkinson’s sufferers, delivered only to viewers who have self-identified as being impacted in ...

As asthma symptoms worsen, patients typically rely on short-acting β 2-agonist (SABA) rescue therapy, but SABAs do not address worsening inflammation, which leaves patients at risk for severe asthma ...